vs
ABVC BIOPHARMA, INC.（ABVC）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是ABVC BIOPHARMA, INC.的2863.7倍（$2.3B vs $796.0K）。渤健净利率更高（-2.1% vs -256.6%，领先254.5%）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs -7.1%）。过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs -0.2%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
ABVC vs BIIB — 直观对比
营收规模更大
BIIB
是对方的2863.7倍
$796.0K
营收增速更快
ABVC
高出111.6%
-7.1%
净利率更高
BIIB
高出254.5%
-256.6%
两年增速更快
ABVC
近两年复合增速
-0.2%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $2.3B |
| 净利润 | $-2.0M | $-48.9M |
| 毛利率 | 100.0% | 78.3% |
| 营业利润率 | -246.8% | -2.5% |
| 净利率 | -256.6% | -2.1% |
| 营收同比 | 104.5% | -7.1% |
| 净利润同比 | -417.4% | -118.3% |
| 每股收益（稀释后） | $-0.09 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCBIIB
| Q4 25 | — | $2.3B | ||
| Q3 25 | $796.0K | $2.5B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | $2.0K | $2.5B | ||
| Q3 24 | $389.3K | $2.5B | ||
| Q2 24 | $117.1K | $2.5B | ||
| Q1 24 | $1.2K | $2.3B |
净利润ABVCBIIB
| Q4 25 | — | $-48.9M | ||
| Q3 25 | $-2.0M | $466.5M | ||
| Q2 25 | — | $634.8M | ||
| Q1 25 | — | $240.5M | ||
| Q4 24 | $-731.6K | $266.7M | ||
| Q3 24 | $-394.8K | $388.5M | ||
| Q2 24 | $-942.3K | $583.6M | ||
| Q1 24 | $-2.8M | $393.4M |
毛利率ABVCBIIB
| Q4 25 | — | 78.3% | ||
| Q3 25 | 100.0% | 73.4% | ||
| Q2 25 | — | 77.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | 100.0% | 76.2% | ||
| Q3 24 | 99.9% | 74.1% | ||
| Q2 24 | 99.8% | 77.8% | ||
| Q1 24 | 77.0% | 76.3% |
营业利润率ABVCBIIB
| Q4 25 | — | -2.5% | ||
| Q3 25 | -246.8% | 22.0% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | -35837.4% | 11.9% | ||
| Q3 24 | -77.7% | 18.3% | ||
| Q2 24 | -734.2% | 28.3% | ||
| Q1 24 | -235539.8% | 20.3% |
净利率ABVCBIIB
| Q4 25 | — | -2.1% | ||
| Q3 25 | -256.6% | 18.4% | ||
| Q2 25 | — | 24.0% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | -37211.3% | 10.9% | ||
| Q3 24 | -101.4% | 15.8% | ||
| Q2 24 | -804.4% | 23.7% | ||
| Q1 24 | -235203.2% | 17.2% |
每股收益（稀释后）ABVCBIIB
| Q4 25 | — | $-0.35 | ||
| Q3 25 | $-0.09 | $3.17 | ||
| Q2 25 | — | $4.33 | ||
| Q1 25 | — | $1.64 | ||
| Q4 24 | $-0.02 | $1.82 | ||
| Q3 24 | $-0.03 | $2.66 | ||
| Q2 24 | $-0.08 | $4.00 | ||
| Q1 24 | $-0.29 | $2.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | — |
| 总债务越低越好 | — | $6.3B |
| 股东权益账面价值 | $12.1M | $18.3B |
| 总资产 | $21.2M | $29.4B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资ABVCBIIB
| Q4 25 | — | — | ||
| Q3 25 | $257.2K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $313.1K | — | ||
| Q3 24 | $208.2K | — | ||
| Q2 24 | $200.0K | — | ||
| Q1 24 | $106.4K | — |
总债务ABVCBIIB
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.3B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $6.3B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $6.3B | ||
| Q1 24 | — | $6.3B |
股东权益ABVCBIIB
| Q4 25 | — | $18.3B | ||
| Q3 25 | $12.1M | $18.2B | ||
| Q2 25 | — | $17.6B | ||
| Q1 25 | — | $17.0B | ||
| Q4 24 | $1.2M | $16.7B | ||
| Q3 24 | $1.6M | $16.4B | ||
| Q2 24 | $1.8M | $15.9B | ||
| Q1 24 | $1.7M | $15.2B |
总资产ABVCBIIB
| Q4 25 | — | $29.4B | ||
| Q3 25 | $21.2M | $29.2B | ||
| Q2 25 | — | $28.3B | ||
| Q1 25 | — | $28.0B | ||
| Q4 24 | $7.5M | $28.0B | ||
| Q3 24 | $7.8M | $28.3B | ||
| Q2 24 | $8.0M | $26.8B | ||
| Q1 24 | $8.0M | $26.6B |
负债/权益比ABVCBIIB
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.28× | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $511.9M |
| 自由现金流经营现金流 - 资本支出 | — | $468.0M |
| 自由现金流率自由现金流/营收 | — | 20.5% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.1B |
8季度趋势，按日历期对齐
经营现金流ABVCBIIB
| Q4 25 | — | $511.9M | ||
| Q3 25 | $-964.7K | $1.3B | ||
| Q2 25 | — | $160.9M | ||
| Q1 25 | — | $259.3M | ||
| Q4 24 | $-702.1K | $760.9M | ||
| Q3 24 | $60.2K | $935.6M | ||
| Q2 24 | $-211.4K | $625.8M | ||
| Q1 24 | $-955.8K | $553.2M |
自由现金流ABVCBIIB
| Q4 25 | — | $468.0M | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $222.2M | ||
| Q4 24 | — | $721.6M | ||
| Q3 24 | — | $900.6M | ||
| Q2 24 | — | $592.3M | ||
| Q1 24 | — | $507.3M |
自由现金流率ABVCBIIB
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 48.4% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 22.1% |
资本支出强度ABVCBIIB
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 2.0% |
现金转化率ABVCBIIB
| Q4 25 | — | — | ||
| Q3 25 | — | 2.73× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 2.85× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 1.07× | ||
| Q1 24 | — | 1.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABVC
暂无分部数据
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
